Teva Pharmaceutical Non-GAAP EPS of $1.00 beats by $0.24, revenue of $4.46B beats by $450M
https://seekingalpha.com/news/4060531-teva-pharmaceutical-non-gaap-eps-of-1_00-beats-0_24-revenue-of-4_46b-beats-450m?source=feed_tag_israel
Jan 31, 2024 - Teva Pharmaceutical reports strong Q4 earnings, exceeding expectations.
0
Teva to divest API unit to focus on core business strengths
https://seekingalpha.com/news/4060502-teva-to-divest-api-unit-to-focus-on-core-business-strengths?source=feed_tag_israel
Jan 31, 2024 - Teva plans to divest its API business as part of its growth strategy, aiming to focus on core strengths and capitalize on opportunities in the global API...
0
Teva earnings preview: Israeli drugmaker to report early Wednesday
https://seekingalpha.com/news/4060267-teva-earnings-preview-israeli-drugmaker-to-report-early-wednesday?source=feed_tag_israel
Jan 30, 2024 - Teva Pharmaceutical Industries (TEVA) is expected to report higher Q4 earnings before market open on Wednesday, with investors looking to see if the Israeli dru
0
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
https://www.cnbc.com/2024/01/28/big-pharma-merck-bristol-myers-jj-prepare-to-lose-revenue.html
Jan 28, 2024 - Fast-approaching patent expirations will take a bite out of revenues and put the industry's top players in the hot seat over the next few years.
0
Unveiling Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Outlook: Wall Street Estimates for Key Metrics
https://www.zacks.com/stock/news/2216435/unveiling-teva-pharmaceutical-industries-ltd-teva-q4-outlook-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2216435
Jan 26, 2024 - Besides Wall Street's top -and-bottom-line estimates for Teva Pharmaceutical Industries Ltd. (TEVA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
0
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
https://www.zacks.com/commentary/2215536/3-generic-drug-stocks-to-watch-amid-improving-market-prospects?cid=CS-ZC-FT-industry_outlook-2215536
Jan 25, 2024 - With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY and TEVA.
0
Teva raised to Buy at Jefferies citing a positive setup ahead of 2024 outlook
https://seekingalpha.com/news/4057313-teva-stock-raised-buy-jefferies?source=feed_tag_israel
Jan 23, 2024 - Jefferies upgrades Teva Pharmaceutical (TEVA) to Buy from Hold ahead of the company's 2024 outlook citing multiple tailwinds to its business. Read more here.
0
Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx
https://www.zacks.com/stock/news/2212909/exelixis-exel-reports-positive-eu-patent-ruling-for-cabometyx?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2212909
Jan 19, 2024 - Exelixis (EXEL) gets a favorable ruling from the European Patent Office in a lawsuit related to its oral oncology drug, Cabometyx.
0
Teva Pharmaceutical Industries Limited (TEVA) Presents at J.P. Morgan 42nd Annual Global Healthcare Conference (Transcript)
https://seekingalpha.com/article/4661970-teva-pharmaceutical-industries-limited-teva-presents-j-p-morgan-42nd-annual-global-healthcare?source=feed_tag_israel
Jan 09, 2024 - Teva Pharmaceutical Industries Limited (NYSE:NYSE:TEVA) J.P.
0
Piper Sandler raises Teva to neutral, stock up 4%
https://seekingalpha.com/news/4052045-piper-sandler-raises-teva-to-neutral-stock-climbs?source=feed_sector_healthcare
Jan 03, 2024 - Piper Sandler has upgraded Teva (TEVA) to neutral, citing the company’s efforts to lower its debt and “lean into its brand assets." The investment bank added, h
0